For prescribing information, click here

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience

Resources

Neuroendocrine Tumours (NETs)

Somatuline® Autogel® (lanreotide) therapeutic indications

Somatuline® Autogel® is indicated in adults for:

  • The treatment of Grade 1 and a subset of Grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin (where hindgut have been excluded), in adults with unresectable locally advanced or metastatic disease.
  • Treatment of symptoms associated with carcinoid tumours.
  • Please visit the PI link at the top of this page for the full list of indications.

Information for HCPs

Somatuline<sup>®</sup> Autogel<sup>®</sup> (lanreotide) Symptom Control in Functional NETs
Somatuline® Autogel® (lanreotide) Symptom Control in Functional NETs
PDF / PowerPoint Deck 2 pages

This leaflet provides information on efficacy, symptom control, and patient experience when using Somatuline® Autogel®.

SOM-IE-000738 | September 2025
Patient Self Injection Support Programme
Patient Self Injection Support Programme
PDF / PowerPoint Deck 5 pages

This booklet provides information on the TCP Homecare service for self-partner injection training.

SOM-IE-000737 | September 2025

Resources for Your Patients

NET Patient Journal
NET Patient Journal
PDF / PowerPoint Deck 42 pages

This booklet provides diary space for patients to record important information, like contact details for the medical team and the dates and times of the next appointment; it also includes a food and symptoms tracker, as well as some useful tips to help manage certain symptoms.

SOM-IE-000733 | September 2025
Living – A part of your guide to Neuroendocrine Tumours (NETs)
Living – A part of your guide to Neuroendocrine Tumours (NETs)
PDF / PowerPoint Deck 24 pages

This handbook is designed to help patients with the day-to-day reality of living with NETs. It gives clear, practical advice on talking about diagnosis, as well as managing the symptoms and emotional, physical and social challenges of living with NETs.

SOM-IE-000732 | August 2025
Glossary
Glossary
PDF / PowerPoint Deck 20 pages

A glossary of terms to do with NETs.

SOM-IE-000731 | August 2025
Learning – A part of your guide to Neuroendocrine Tumours (NETs)
Learning – A part of your guide to Neuroendocrine Tumours (NETs)
PDF / PowerPoint Deck 48 pages

This booklet is designed to help patients understand the what, where, who and how of NETs, as well as potential symptoms, tests and treatments associated with NETs.

SOM-IE-000730 | August 2025

Administration Technique Videos

1-2-3 A Guide to Self, or Carer Injection
1-2-3 A Guide to Self, or Carer Injection
PDF / PowerPoint Deck 12 pages

This booklet describes how to inject Somatuline® Autogel®, and contains the full, step-by-step instructions on the correct procedure for giving, or being given, the injections.

SOM-IE-000739 | September 2025

Contact your Ipsen representative

Send request
Resources

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

To access relevant information about Neuroendocrine Tumours (NETs), please choose one of the following options:

I am a Healthcare Professional in Ireland

This section of the website is for healthcare professionals in Ireland only and contains promotional content regarding our medicines

I am a Healthcare Professional in Ireland

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

I am a patient

This section provides information to support patients that have been prescribed Somatuline® Autogel® (lanreotide). It has been designed for Irish patients and should not replace the details contained in the Patient Information Leaflet.

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.